K2M Group Holdings (KTWO) Receives Consensus Rating of “Buy” from Brokerages

K2M Group Holdings (NASDAQ:KTWO) has been given an average rating of “Buy” by the fourteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $24.44.

Several analysts have weighed in on the company. BidaskClub downgraded K2M Group from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. Oppenheimer set a $24.00 price objective on K2M Group and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded K2M Group from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. Barclays reiterated a “buy” rating and issued a $25.00 price objective on shares of K2M Group in a research report on Tuesday, January 9th. Finally, Needham & Company LLC boosted their price objective on K2M Group from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th.

NASDAQ:KTWO traded down $0.10 during mid-day trading on Thursday, reaching $19.28. The stock had a trading volume of 15,524 shares, compared to its average volume of 274,143. The company has a market capitalization of $837.82, a price-to-earnings ratio of -22.23 and a beta of 1.47. K2M Group has a one year low of $16.44 and a one year high of $25.99. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.84 and a quick ratio of 1.52.

K2M Group (NASDAQ:KTWO) last announced its quarterly earnings data on Wednesday, February 28th. The medical device company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). K2M Group had a negative net margin of 14.40% and a negative return on equity of 14.85%. The company had revenue of $67.80 million during the quarter, compared to the consensus estimate of $67.36 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. sell-side analysts anticipate that K2M Group will post -0.72 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its stake in shares of K2M Group by 7,765.0% during the third quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after buying an additional 4,659 shares during the period. Teacher Retirement System of Texas purchased a new stake in K2M Group in the fourth quarter worth $213,000. MetLife Investment Advisors LLC purchased a new stake in K2M Group in the fourth quarter worth $350,000. Envestnet Asset Management Inc. purchased a new stake in K2M Group in the third quarter worth $423,000. Finally, Teton Advisors Inc. grew its stake in K2M Group by 300.0% in the fourth quarter. Teton Advisors Inc. now owns 40,000 shares of the medical device company’s stock worth $720,000 after purchasing an additional 30,000 shares during the period. 99.32% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “K2M Group Holdings (KTWO) Receives Consensus Rating of “Buy” from Brokerages” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3371001/k2m-group-holdings-ktwo-receives-consensus-rating-of-buy-from-brokerages.html.

About K2M Group

K2M Group Holdings, Inc, a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Forward Management LLC Lowers Stake in JPMorgan Chase
Forward Management LLC Lowers Stake in JPMorgan Chase
TCI Wealth Advisors Inc. Raises Stake in ExxonMobil
TCI Wealth Advisors Inc. Raises Stake in ExxonMobil
Marcus & Millichap  Set to Announce Quarterly Earnings on Monday
Marcus & Millichap Set to Announce Quarterly Earnings on Monday
AEterna Zentaris  Scheduled to Post Earnings on Monday
AEterna Zentaris Scheduled to Post Earnings on Monday
WageWorks  Set to Announce Quarterly Earnings on Monday
WageWorks Set to Announce Quarterly Earnings on Monday
Pfizer  Shares Sold by Keel Point LLC
Pfizer Shares Sold by Keel Point LLC


© 2006-2018 Ticker Report. Google+.